Medicamen Biotech dividend yield

Per cent unless marked ×
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
—7.22×5.16×7.50×11.64×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.2%————
−11.1%————
—7.22×5.16×7.50×11.64×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MEDICAMEQ₹251.90

Medicamen Biotech Limited

· Pharma & Health
₹ CrorePeersMEDICOAAREYDRUGSNECLIFEHALEOSLABSALBERTDAVDNATCAPSUQVALIANTLABBALPHARMAMcap ₹342 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPontAnnuals · FY-end closes
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Dividend Coverage (PAT/Dividends Paid)11.647.505.167.22—
Earnings Yield %————3.17
FCF Yield %————-11.11
Dividend Coverage (NI/Dvd)11.647.505.167.22—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.